News | April 19, 2021
Vaishali Pharma initiates 30 products registration
The company also plans to register the similar range of products in the neighbouring countries.
The company also plans to register the similar range of products in the neighbouring countries.
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.
Reflecting on the learning during the pandemic, industry is aiming to push innovation in R&D and implement automation and digital technologies across various operational levels.
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.
Subscribe To Our Newsletter & Stay Updated
